Blossomhill Therapeutics Inc (BLSM)

$16.03 -0.35 (-2.14%)
Market Cap 501.95M
Revenue (ttm) 0.00
Net Income (ttm) -60.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 155,900
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 30.64M
Stochastic %K 33%
Beta N/A
Analysts Strong Buy
Price Target N/A
justiceforb_85
justiceforb_85 Aug. 19 at 11:37 PM
$BLSM look forward to possible accelerated approval for BH-30643.
0 · Reply
RTPRwire
RTPRwire Aug. 18 at 11:39 AM
$BLSM is active on FDA approval following a Globe Newswire release. BlossomHill Therapeutics receives FDA Fast Track designation for BH-30643, a macrocyclic EGFR inhibitor for advanced EGFR C797S-positive NSCLC. RTPR pushed this release out to users at 7:00:00 AM ET
0 · Reply
theflynews
theflynews Aug. 10 at 3:18 PM
Opening Day: Biotech names lead week’s IPO activity - $BLSM - https://thefly.com/BLSM
0 · Reply
justiceforb_85
justiceforb_85 Aug. 8 at 3:19 AM
$BLSM added. BH-30643 with compelling activity in post-osimertinib setting, including C797S and T790M NSCLC. Closest competitor is VRN110755 but they are studying their drug outside the US and will therefore have a much lower chance of US approval.
1 · Reply
Latest News on BLSM
BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

2026-08-18T11:10:13.000Z - 6 days ago

BlossomHill Therapeutics receives fast track designation for BH-30643 from FDA

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Aug 18, 2026, 7:00 AM EDT - 6 days ago

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

2026-08-07T19:07:26.000Z - 17 days ago

BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO

BMY JPM

BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00

2026-08-07T16:35:37.000Z - 17 days ago

BlossomHill Therapeutics opens at $15.75, IPO priced at $16.00

BlossomHill Therapeutics 9.375M share IPO priced at $16.00

2026-08-07T03:00:30.000Z - 18 days ago

BlossomHill Therapeutics 9.375M share IPO priced at $16.00

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

Aug 6, 2026, 8:07 PM EDT - 18 days ago

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00

2026-08-04T09:05:35.000Z - 20 days ago

BlossomHill Therapeutics 7.81M share IPO price range $15.00-$17.00

Latigo, BlossomHill launch US IPOs as biotech listings rebound

Aug 3, 2026, 8:25 AM EDT - 21 days ago

Latigo, BlossomHill launch US IPOs as biotech listings rebound

LTGO

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO

Jul 17, 2026, 12:51 AM EDT - 5 weeks ago

Cancer therapies biotech BlossomHill Therapeutics files for a $100 million IPO

BlossomHill Therapeutics IPO Registration Document (S-1)

Jul 16, 2026, 8:13 PM EDT - 5 weeks ago

BlossomHill Therapeutics IPO Registration Document (S-1)

justiceforb_85
justiceforb_85 Aug. 19 at 11:37 PM
$BLSM look forward to possible accelerated approval for BH-30643.
0 · Reply
RTPRwire
RTPRwire Aug. 18 at 11:39 AM
$BLSM is active on FDA approval following a Globe Newswire release. BlossomHill Therapeutics receives FDA Fast Track designation for BH-30643, a macrocyclic EGFR inhibitor for advanced EGFR C797S-positive NSCLC. RTPR pushed this release out to users at 7:00:00 AM ET
0 · Reply
theflynews
theflynews Aug. 10 at 3:18 PM
Opening Day: Biotech names lead week’s IPO activity - $BLSM - https://thefly.com/BLSM
0 · Reply
justiceforb_85
justiceforb_85 Aug. 8 at 3:19 AM
$BLSM added. BH-30643 with compelling activity in post-osimertinib setting, including C797S and T790M NSCLC. Closest competitor is VRN110755 but they are studying their drug outside the US and will therefore have a much lower chance of US approval.
1 · Reply